ILUSTRA

Interleukin-1 Genotypes Are Predictive of Cardiovascular Events in Patients With Elevated Lipoprotein(a)

Second Study Validates Role in Recurrent Cardiac Events

WALTHAM, MA – March 20, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today the presentation of clinical data from “The Ioannina Study” at the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC 2017) in Washington, DC that demonstrates the ability of certain interleukin-1 (IL-1) genetic patterns together with elevated lipoprotein (a) (Lp(a)) to predict recurrent atherosclerotic cardiac events. Dr. Bechlioulis and co-workers reported the new findings from the University Hospital of Ioannina (Greece) along with collaborators from the University of California at San Diego.

In the longitudinal study (median time 43 months) of 1,084 patients who […]

Interleukin Genetics Signs Second Employer Agreement in Pittsburgh Region

Spang & Company to Offer ILUSTRA™ to Employees Through Pittsburgh Business Group on Health Collaboration

WALTHAM, MA – March 13, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has signed an agreement with Spang & Company, a diversified manufacturing company, to offer the ILUSTRA Inflammation Management Program to their employees and their families as an enhancement to the company’s employee benefits plan.

Spang & Company is an employer-member of the Pittsburgh Business Group on Health (PBGH), the region’s leading employer-led coalition and as a member received early access to the ILUSTRA Program. Under the terms of the agreement, ILUSTRA will be made available to all of Spang & […]

Interleukin Genetics Establishes Partnership with Greater Philadelphia Business Coalition on Health

Expands Availability of the ILUSTRATM Inflammation Management Program with Deployment of First Employer in Philadelphia Region

WALTHAM, MA – March 2, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a partnership with the Greater Philadelphia Business Coalition on Health (GPBCH) to make the ILUSTRA Inflammation Management Program available to GPBCH employer-members in the Philadelphia area as part of a company’s enhanced employee benefits plan.

The collaboration is designed to introduce ILUSTRA to coalition members and to assist employer members in implementing and evaluating the innovative ILUSTRA program.

“We’re proud to be working with GPBCH to educate its members on the health benefits that may result […]

Interleukin Genetics Deploys ILUSTRATM Inflammation Management Program with mPulse Mobile Employees

Enhanced Benefit Can Deliver Significant Health and Economic Value by Targeting Chronic Inflammation

WALTHAM, MA – February 23, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with mPulse Mobile, a leader in mobile health engagement, to offer the ILUSTRA Inflammation Management Program to their employees as an enhancement to the company’s employee benefits plan.

“This innovative program is a clear match with our company values and mission,” said Brian Chudleigh, Chief Financial Officer at mPulse Mobile. “Affecting behavioral change toward a healthy lifestyle is the key to realizing long-term health, wellness and reduced healthcare costs. I am impressed with the ILUSTRA program […]

IG and PBGH Forge Relationship To Bring ILUSTRATM To Pittsburgh Employers

WALTHAM, MA – Feb 15, 2017Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with the Pittsburgh Business Group on Health (PBGH) to offer the ILUSTRA™ Inflammation Management Program to PBGH employer-members in the Pittsburgh area as part of a company’s enhanced employee benefits plan.

“PBGH is the region’s leading employer-led coalition designed to drive transparency in health care data, cost and quality. Western Pennsylvania has a history of health care innovation and we are delighted to be working together to build on this heritage,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “This relationship advances our commercial strategy by providing […]

Interleukin Genetics Launches the ILUSTRA Inflammation Management Program

Easy-to-deploy benefit enhancement can deliver significant health and economic value by targeting chronic inflammation

WALTHAM, Mass., November 3, 2016 — Interleukin Genetics, Inc. (OTCQB:ILIU) a life science company focused on the genetics of chronic inflammation, today unveiled the  ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation. Under supervision of a licensed dentist or physician, ILUSTRA is offered by employers and through select insurance carriers as an enhanced benefit that has potential to provide significant health and economic value by improving the management of chronic inflammation.

ILUSTRA incorporates three components: 1) a simple yet technologically advanced genetic risk test; 2) targeted education to healthcare professionals to individualize care […]